Latest Conference

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

A look at upcoming presentations at APSARD 2026, January 15-18.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Experts discuss the significant impact of tardive dyskinesia, emphasizing the need for better recognition and treatment strategies in patient care.

What is the neuroplasticity hypothesis and why is it more important now than ever?

Discover insights on bipolar disorder diagnosis and treatment challenges, emphasizing the importance of accurate assessment for effective care.

The language clinicians use while talking to postpartum patients is critical. Learn more on best practices in treating this unique patient population.

Alejandro Alva, MD, offers insights on the use of prescription digital therapeutics for substance use disorders at the Southern Florida Psychiatry Conference.

Conferences: the perfect networking opportunity.

Long-acting injectables enhance stability and adherence in patients with psychosis, improving long-term outcomes and quality of life, shares Erin Crown, MHS, PA-C, Psych-CAQ.

Gerald A. Maguire, MD highlights the need for psychiatric awareness and treatment of stuttering at the 2025 Southern Florida Psychiatry Conference.

Shulamit Bossewitch discussed nonpharmacological support for postpartum depression at the 2025 Southern Florida Psychiatry Conference.

How can the glutamate model overcome challenges in treating major depressive disorder?